William Blair
http://www.williamblair.comWilliam Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, it has been committed to helping clients achieve their financial objectives.
View Older Stories View More Recent Stories
-
William Blair reiterates 'outperform' on Freshpet (FRPT) following CEO meeting
-
BlackArch Partners Advises Windjammer Capital Investors on Sale of Hermetic Solutions Group to Arcline Investment Management
-
William Blair Continues Investment Banking Growth With Consumer and Retail Managing Director
-
Bynder Announces Majority Investment from Thomas H. Lee Partners
-
William Blair reiterates 'outperform' on PagerDuty (PD) following management meetings
-
William Blair reiterates 'outperform' on DigitalOcean (DOCN) after meetings with CEO and CFO
-
Palantir (PLTR) FALCON contract is officially 'nevermore' - William Blair
-
William Blair Starts Newamsterdam Pharma Co NV (NAMS) at Outperform
-
AVISTA CAPITAL PARTNERS ACQUIRES SPEAR EDUCATION
-
William Blair Assumes Traeger Inc. (COOK) at Market Perform, 'Continue to Like Long-Term Positioning Though Inventory Overhang Creates Near-Term Hole'
-
Harrow Secures Capital to Close Recently Announced Acquisition
-
MasterControl Raises $150M Series A Funding Round from Sixth Street Growth at Valuation of $1.3B
-
MasterControl Raises $150M Series A Funding Round from Sixth Street Growth at Valuation of $1.3B
-
Harrow Health (HROW) to offer $100 million of senior notes due in 2027
-
Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones
-
H.I.G. Sells Majority Interest in Milestone Technologies
-
binx health to Participate in William Blair’s Innovator Series: Life Science Tools and Diagnostics
-
Amgen dives deeper into rare disease drugs with $27.8 billion Horizon deal
-
Shift (SFT) Closes Merger with CarLotz (LOTZ)
-
Shift Closes Merger with CarLotz, Creating a Differentiated Used Omnichannel Auto Retailer, and Announces Shift Board of Directors Changes
-
Shift Closes Merger with CarLotz, Creating a Differentiated Used Omnichannel Auto Retailer, and Announces Shift Board of Directors Changes
-
Shift Closes Merger with CarLotz, Creating a Differentiated Used Omnichannel Auto Retailer, and Announces Shift Board of Directors Changes
-
Shift Closes Merger with CarLotz, Creating a Differentiated Used Omnichannel Auto Retailer, and Announces Shift Board of Directors Changes
-
Autolus Therapeutics (AUTL) Prices 75M Share Offering at $2
-
Autolus Announces Pricing of Public Offering
-
Autolus Announces Pricing of Public Offering
-
Autolus Therapeutics (AUTL) Announces Proposed Public Offering in the United States
-
Autolus Announces Proposed Public Offering in the United States
-
Autolus Announces Proposed Public Offering in the United States
-
Saratoga Investment Corp. Prices Public Offering of $52.5 Million 8.125% Notes Due 2027
-
Saratoga Investment Corp. Prices Public Offering of $52.5 Million 8.125% Notes Due 2027
-
Saratoga Investment Corp. Announces Offering of Notes and BBB+ Investment Grade Rating from Egan-Jones Ratings Company
-
Saratoga Investment Corp. Announces Offering of Notes and BBB+ Investment Grade Rating from Egan-Jones Ratings Company
-
First Women’s Bank announces new Mission Partners Airbnb, BCG, Principal®, Salesforce and Envestnet have joined the Bank to help close the gender gap in access to capital
-
William Blair on Wayfair (W): 'Early Signs of Strong Holiday Demand Suggests Upside in the Upcoming Fourth Quarter'
-
Form 497K WILLIAM BLAIR FUNDS
-
Form 497K WILLIAM BLAIR FUNDS
-
Form 497 WILLIAM BLAIR FUNDS
-
William Blair Reiterates Outperform Rating on Gogo (GOGO) as Business Jet Traffic Hits a Five-Month High
-
NewAmsterdam Pharma (NAMS) Debuts as Publicly Traded Company
-
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential
-
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential
-
William Blair Upgrades Neogen (NEOG) to Outperform
-
Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30
-
Form NPORT-P WILLIAM BLAIR FUNDS For: Sep 30

